|
Prof Graham Boulnois Chairman
Dr Mark Payton Chief Executive Officer
Prof John Bell Non Executive Director
Dr Stuart Collinson Non Executive Director
Dr Luke Evnin Non Executive Director
Dr Anja König Non Executive Director
|
|
Dr Luke Evnin
Non Executive Director
Dr. Luke Evnin joined the board of directors of Oxagen in
May 2005. He is a general partner at MPM Capital which he
joined in 1998 to launch MPM’s first venture fund and established
the San Francisco office for the firm in 1999. Previously
Luke was at Accel Partners for over seven years including
four as a General Partner. He was involved in biopharmaceutical,
medical device and healthcare service companies for Accel’s
funds III, IV and V. He is currently a Director of BioValve,
Enteromedics, Innovative Spinal Technologies, Intercell,
Metabasis, Peptimmune and Restore Medical and was previously
a Director at Idun Pharmaceuticals, Oscient Sonic Innovations,
Epic Therapeutics, EPIX Medical, Signal Pharmaceuticals as
well as several other private companies.
Luke earned his PhD in the Department of Biochemistry at
the University of California-San Francisco, and he received
his AB in Molecular Biology magna cum laude from Princeton
University.
|